<DOC>
	<DOCNO>NCT01617187</DOCNO>
	<brief_summary>The purpose trial ass effect asenapine 2.5 5 mg sublingually twice daily ( BID ) compare placebo treatment schizophrenia ( overall symptom ) measure Positive Negative Syndrome Scale ( PANSS ) . Olanzapine administer 15 mg orally daily ( QD ) use active control . The primary hypothesis least one asenapine dose superior placebo improve schizophrenia symptom measure change Baseline PANSS total score Day 42 . The first key secondary hypothesis least one asenapine dose superior placebo improve schizophrenia symptom measure change Baseline Clinical Global Impression Scale-Severity ( CGI-S ) score Day 42 . The second key secondary hypothesis least one asenapine dose superior placebo improve schizophrenia symptom measure rate PANSS responder ( ≥30 % Reduction From Baseline PANSS Total Score ) Day 42 .</brief_summary>
	<brief_title>A Study Efficacy Safety Asenapine Participants With Acute Exacerbation Schizophrenia ( P05688 )</brief_title>
	<detailed_description>The trial consist screening/tapering period , treatment period , follow-up period . The 6-week active treatment period include inpatient phase outpatient phase . Participants complete trial may continue treatment long-term extension protocol ( P05689 ) . Participants continue treatment continuation trial ( whether complete 6-week trial discontinue prematurely ) follow-up visit 7 day last dose trial medication .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Current diagnosis schizophrenia paranoid , disorganize , undifferentiated subtype Minimum PANSS total score 70 Screening Baseline Score least 4 ( moderate ) two five item positive subscale PANSS Confirmed experience acute exacerbation schizophrenia CGIS scale score least 4 ( moderately ill ) Baseline Has respond positively antipsychotic medication clozapine ( Clozaril® ) prior episode Body mass index ( BMI ) &lt; 18.5 &gt; 40.0 kg/m^2 Laboratory and/or clinical evidence clinically significant hepatic condition Known history , undergo treatment , narrow angle glaucoma Diagnosed epilepsy seizure disorder beyond childhood febrile seizure Known serological evidence human immunodeficiency virus ( HIV ) antibody History neuroleptic malignant syndrome tardive dyskinesia Past current diagnosis schizoaffective disorder , schizophrenia residual subtype , schizophrenia catatonic subtype , current diagnosis schizophrenia course specifier continuous , single episode partial remission , single episode full remission , borderline personality disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>